Personalis, Inc. (PSNL)
15.65
-0.28
(-1.76%)
USD |
NASDAQ |
Oct 16, 16:00
15.66
+0.01
(+0.06%)
After-Hours: 20:00
Personalis Research and Development Expense (Annual) : 50.26M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 50.26M |
| December 31, 2024 | 48.90M |
| December 31, 2023 | 64.78M |
| December 31, 2022 | 64.91M |
| December 31, 2021 | 49.31M |
| Date | Value |
|---|---|
| December 31, 2020 | 28.57M |
| December 31, 2019 | 22.42M |
| December 31, 2018 | 14.30M |
| December 31, 2017 | 9.919M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Tempus AI, Inc. | 319.03M |
| 10X Genomics, Inc. | 238.63M |
| Alamar Biosciences, Inc. (California) | 37.47M |
| Champions Oncology, Inc. | 9.084M |
| Medpace Holdings, Inc. | -- |